Canadian expert group consensus recommendations:KRAS testing in colorectal cancer

Current Oncology

Volumn 18, Issue 4, 2011, Pages

  Aubin, Francine ^a   Gill, S ^b   Burkes, R ^c   Colwell, B ^d   Kamel Reid, S ^e   Koski, S ^f   Pollett, A ^c   Samson, B ^g   Tehfe, M ^a   Wong, R ^h   Young, S ^b   Soulieres D ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Mount Sinai Family Medicine Centre   (Canada)

^d Nova Scotia Cancer Centre   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g HÔPITAL CHARLES LEMOYNE   (Canada)

^h CANCERCARE MANITOBA   (Canada)

Author keywords

Anti EGFR therapy; BRAF mutations testing; Cetuximab; Consensus recommendations; Guidelines; Kras mutations testing; Metastatic colorectal cancer; Panitumumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; BRAF GENE; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CODON; COLORECTAL CANCER; CONSENSUS; FUNDING; GENE MUTATION; GENETIC SCREENING; HUMAN; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PRACTICE GUIDELINE; PROTO ONCOGENE; TURNAROUND TIME;

EID: 80051535563     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i4.779     Document Type: Article

References (22)

1. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
3. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254-61.
4. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
5. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
7. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
8. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study. J Clin Oncol 2010;28:4697-705.
9. Cancer Care Ontario (cco). Home>CCO Toolbox>Drug Formulary [Web resource]. Toronto, ON: cco; 2011. Available at: www.cancercare.on.ca/cms/One.aspx?portalId=1377&pageId=10760 (search for the cetu or pntm chemotherapy regimen); cited June 27, 2011.
10. BC Cancer Agency (bcca). Home>Health Professionals Info>Chemotherapy Protocols>Gastrointestinal>Unresectable Colorectal Cancer (advanced) [Web resource]. Vancouver, BC: bcca; 2010. [Available at: www.bccancer.bc.ca/HPI/ChemotherapyProtocols/Gastrointestinal/default. htm#unresectable (see the ugiavcetir or ugiavpani protocol); cited June 27, 2011].
11. Soulières D, Greer W, Magliocco AM, et al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-egfr therapies. Curr Oncol 2010;17(suppl 1):S31-40
12. Tournigand C, André T, Achille, E, et al. folfiri followed by folfox6 or the reverse sequence in advanced colorectal cancer: a randomized gercor study. J Clin Oncol 2004;22:229-37.
13. National Institute for Health and Clinical Excellence (nice). Home>Find guidance>NICE guidance by type>Technology appraisals>Published appraisals>Colorectal cancer (first line)-cetuximab [Web page]. London, U.K.: nice; 2011. [Available at: guidance.nice.org.uk/TA176; cited June 27, 2011]
14. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer J 2009;15:110-13.
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
16. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008;13:1270-5.
17. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009;27:1130-6.
18. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-typeBRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.
19. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and egfr status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009;27:5924-30.
20. Van Cutsem E, Lang I, Folprecht G, et al. Cetuximab plus folfiri: final data from the crystal study on the association of KRAS and BRAF biomarker status with treatment outcome [abstract 3570]. J Clin Oncol 2010;28:. Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=54429; cited May 31, 2011]
21. Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E. Cetuximab with chemotherapy (ct) as first-line treatment for metastatic colorectal cancer (mcrc): analysis of the crystal and opus studies according to KRAS and BRAF mutation status [abstract 3506]. J Clin Oncol 2010;28:.Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=54429; cited May 31, 2011.
22. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-9.